Chalcones as Multifaceted Modulators in Non-Small Cell Lung Cancer
Overview
Chalcones exhibit anticancer properties in non-small cell lung cancer (NSCLC) through various mechanisms, including apoptosis induction and cell cycle arrest. Their structural tunability allows for the design of derivatives with enhanced activity.
Background
Lung cancer, particularly NSCLC, is a leading cause of cancer-related mortality globally, with significant challenges in treatment due to resistance and severe side effects of current therapies. Existing treatments often fail to provide lasting benefits.
Data Highlights
Recent preclinical studies demonstrate that chalcones can induce apoptosis, arrest the cell cycle, and inhibit angiogenesis in NSCLC models.
Key Findings
Chalcones possess anti-inflammatory, antioxidant, and anticancer properties.
They can induce apoptosis and inhibit tumor progression in NSCLC models.
Structural modifications of chalcones can enhance their selectivity and potency.
Chalcones modulate pathways related to epithelial–mesenchymal transition and redox homeostasis.
Current research is fragmented, highlighting the need for integrative studies on chalcone mechanisms.
Clinical Implications
Chalcones may serve as a basis for developing new therapeutic agents in NSCLC.
Conclusion
Chalcones represent a class of compounds for NSCLC treatment, warranting further investigation into their mechanisms.
